Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
1(20%)
Results Posted
100%(1 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
25.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

recruiting120%
terminated360%
completed120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_1

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

NCT04187443
terminatedphase_1

A Study Of The Selective PKC-β Inhibitor MS- 553

NCT03492125
terminatedphase_1

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

NCT05720052
terminatedphase_1

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

NCT05272813
completedphase_1

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

NCT02406989

Clinical Trials (5)

Showing 5 of 5 trials
NCT04187443Phase 1

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Recruiting
NCT03492125Phase 1

A Study Of The Selective PKC-β Inhibitor MS- 553

Terminated
NCT05720052Phase 1

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Terminated
NCT05272813Phase 1

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Terminated
NCT02406989Phase 1

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5